ES2796089T3 - Análogos de dioxano de uridina para el tratamiento de cáncer - Google Patents
Análogos de dioxano de uridina para el tratamiento de cáncer Download PDFInfo
- Publication number
- ES2796089T3 ES2796089T3 ES15756888T ES15756888T ES2796089T3 ES 2796089 T3 ES2796089 T3 ES 2796089T3 ES 15756888 T ES15756888 T ES 15756888T ES 15756888 T ES15756888 T ES 15756888T ES 2796089 T3 ES2796089 T3 ES 2796089T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- mmol
- compound
- phenyl
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- QOEZZBYEIFUJOF-LDEAUMELSA-N CC(C)CCC(C)C(NC(C=CN1[C@H]2O[C@@H](COP(N[C@@H](C)C(OC)=O)(Oc(cc3)ccc3Br)=O)OC2)=NC1=O)=O Chemical compound CC(C)CCC(C)C(NC(C=CN1[C@H]2O[C@@H](COP(N[C@@H](C)C(OC)=O)(Oc(cc3)ccc3Br)=O)OC2)=NC1=O)=O QOEZZBYEIFUJOF-LDEAUMELSA-N 0.000 description 1
- WJWRISWOANPOFA-YXTPANNBSA-N C[C@@H](C(OC)=O)NP(OC[C@@H](OC1)O[C@@H]1N(C=CC(N)=N1)C1=O)(Oc(cc1)ccc1Br)=O Chemical compound C[C@@H](C(OC)=O)NP(OC[C@@H](OC1)O[C@@H]1N(C=CC(N)=N1)C1=O)(Oc(cc1)ccc1Br)=O WJWRISWOANPOFA-YXTPANNBSA-N 0.000 description 1
- BWJABVFLLSLHBF-HOTGVXAUSA-N C[C@@H](C(OCC(C)(C)C)=O)NP(N[C@@H](C)C(OCC(C)(C)C)=O)(Oc(cc1)ccc1[N+]([O-])=O)=O Chemical compound C[C@@H](C(OCC(C)(C)C)=O)NP(N[C@@H](C)C(OCC(C)(C)C)=O)(Oc(cc1)ccc1[N+]([O-])=O)=O BWJABVFLLSLHBF-HOTGVXAUSA-N 0.000 description 1
- AFGDZTXURXCRAM-UHFFFAOYSA-N NC(C=CN1C2OC(COP(Oc3ccccc3)=O)OC2)=NC1=O Chemical compound NC(C=CN1C2OC(COP(Oc3ccccc3)=O)OC2)=NC1=O AFGDZTXURXCRAM-UHFFFAOYSA-N 0.000 description 1
- RXRGZNYSEHTMHC-BQBZGAKWSA-N NC(C=CN1[C@H]2O[C@@H](CO)OC2)=NC1=O Chemical compound NC(C=CN1[C@H]2O[C@@H](CO)OC2)=NC1=O RXRGZNYSEHTMHC-BQBZGAKWSA-N 0.000 description 1
- GVBHKNVCIKUPCZ-UHFFFAOYSA-N Oc(cc1)ccc1C(C1CC1)=O Chemical compound Oc(cc1)ccc1C(C1CC1)=O GVBHKNVCIKUPCZ-UHFFFAOYSA-N 0.000 description 1
- HZCPODPQEZHXHM-UHFFFAOYSA-N Oc(cc1)ccc1C(CCCCl)=O Chemical compound Oc(cc1)ccc1C(CCCCl)=O HZCPODPQEZHXHM-UHFFFAOYSA-N 0.000 description 1
- NCPBESHYZRJICR-UHFFFAOYSA-N [O-][N+](c(cc1)ccc1OP(Cl)(Cl)=O)=O Chemical compound [O-][N+](c(cc1)ccc1OP(Cl)(Cl)=O)=O NCPBESHYZRJICR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1450983 | 2014-08-25 | ||
| SE1550858 | 2015-06-22 | ||
| PCT/EP2015/069370 WO2016030335A1 (en) | 2014-08-25 | 2015-08-24 | Dioxolane analogues of uridine for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2796089T3 true ES2796089T3 (es) | 2020-11-25 |
Family
ID=54014804
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15756888T Active ES2796089T3 (es) | 2014-08-25 | 2015-08-24 | Análogos de dioxano de uridina para el tratamiento de cáncer |
| ES19177824T Active ES2927212T3 (es) | 2014-08-25 | 2015-08-24 | Análogos de dioxano de uridina para el tratamiento de cáncer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19177824T Active ES2927212T3 (es) | 2014-08-25 | 2015-08-24 | Análogos de dioxano de uridina para el tratamiento de cáncer |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US10144750B2 (enExample) |
| EP (2) | EP3186244B1 (enExample) |
| JP (2) | JP6663424B2 (enExample) |
| KR (2) | KR102398714B1 (enExample) |
| CN (4) | CN111269264A (enExample) |
| AU (2) | AU2015308988C1 (enExample) |
| BR (1) | BR112017003898B1 (enExample) |
| CA (2) | CA2956251C (enExample) |
| CY (1) | CY1122945T1 (enExample) |
| DK (2) | DK3572410T3 (enExample) |
| EA (2) | EA033300B1 (enExample) |
| ES (2) | ES2796089T3 (enExample) |
| HR (1) | HRP20201023T1 (enExample) |
| HU (2) | HUE050705T2 (enExample) |
| IL (2) | IL250344B (enExample) |
| MX (1) | MX369649B (enExample) |
| MY (2) | MY188089A (enExample) |
| NZ (2) | NZ729118A (enExample) |
| PH (2) | PH12017500184A1 (enExample) |
| PL (2) | PL3572410T3 (enExample) |
| PT (2) | PT3186244T (enExample) |
| SG (3) | SG10202001117YA (enExample) |
| WO (1) | WO2016030335A1 (enExample) |
| ZA (1) | ZA201802864B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102398714B1 (ko) * | 2014-08-25 | 2022-05-17 | 메디비르 아베 | 암 치료를 위한 우리딘의 디옥솔란 유사체 |
| CN106543220A (zh) * | 2015-09-16 | 2017-03-29 | 博瑞生物医药（苏州）股份有限公司 | 氨基磷酸酯化合物及其制备方法和晶体 |
| RS62593B1 (sr) | 2015-12-11 | 2021-12-31 | NuCana plc | Dijastereoselektivna sinteza derivata fosfata i proleka gemcitabina nuc-1031 |
| CA3014769C (en) * | 2016-03-02 | 2024-01-09 | Medivir Aktiebolag | Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine |
| CN106432328B (zh) * | 2016-09-14 | 2019-03-22 | 江苏福瑞生物医药有限公司 | 一种索非布韦中间体的制备方法 |
| MA46839A (fr) * | 2016-11-18 | 2021-03-24 | Neurovive Pharmaceutical Ab | Promédicaments hépatiques d'ionophores de protons mitochondriaux |
| GB201709471D0 (en) * | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| WO2019245444A1 (en) | 2018-06-21 | 2019-12-26 | Medivir Ab | Base-modified cytidine nucleotides for leukemia therapy |
| JP7337539B2 (ja) * | 2018-06-21 | 2023-09-04 | メディヴィル・アクチエボラーグ | 白血病療法のための塩基修飾シチジンヌクレオチド |
| WO2020171757A1 (en) * | 2019-02-18 | 2020-08-27 | Medivir Aktiebolag | Methods for treating liver cancers using an orally administered dioxolane nucleotide in combination with an anti-pd1 or anti-pdl1 monoclonal antibody |
| CN110964057B (zh) * | 2019-12-25 | 2022-05-06 | 东南大学 | 一种利用微流体反应装置制备索非布韦中间体的方法 |
| CN113402546A (zh) * | 2020-03-17 | 2021-09-17 | 浙江四维医药科技有限公司 | 一种瑞德西韦磷酸中间体尾链动态动力学拆分方法 |
| JP7709456B2 (ja) * | 2020-04-15 | 2025-07-16 | メディヴィル・アクチエボラーグ | 肝臓癌のためのｍｉｖ－８１８／レンバチニブ併用療法 |
| CN113754692B (zh) * | 2020-06-03 | 2022-06-10 | 上海交通大学 | 瑞德西韦中间体(s,s)-氨基磷酸酯的不对称催化合成方法 |
| CN114685558A (zh) * | 2020-12-28 | 2022-07-01 | 尚科生物医药（上海）有限公司 | 一种瑞德西韦中间体的制备方法 |
| CN114249764A (zh) * | 2021-11-10 | 2022-03-29 | 宁波大学 | 一种磷酰胺酯类前药的中间体及其制备方法与应用 |
| WO2025155547A1 (en) * | 2024-01-17 | 2025-07-24 | University Of Georgia Research Foundation, Inc. | An efficient synthesis of beta-l-5-[(e)-2-bromovinyl)-1-((2s,4s)-2-(hydroxymethyl)-1,3-(dioxolane-4-yl) uracil)] (l-bhdu) via chiral pure l-dioxolane |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5444063A (en) * | 1990-12-05 | 1995-08-22 | Emory University | Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity |
| US6022876A (en) * | 1996-11-15 | 2000-02-08 | Yale University | L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections |
| KR20030096226A (ko) * | 2000-10-13 | 2003-12-24 | 샤이어 바이오켐 인코포레이티드 | 개선된 세포간 전달을 보이는 디옥소란 동족체 |
| GB0317009D0 (en) * | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| WO2007106450A2 (en) * | 2006-03-10 | 2007-09-20 | University Of Georgia Research Foundation, Inc. | Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase in combination therapy |
| KR20090057050A (ko) * | 2006-09-01 | 2009-06-03 | 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 | 암치료를 위한 트록사시타빈 전구약물 |
| PL216525B1 (pl) * | 2006-10-17 | 2014-04-30 | Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk | 5'-O-[(N-acylo)amidoditiofosforano] nukleozydy oraz sposób wytwarzania 5'-O-[(N-acylo)amidofosforano]-,5'-O-[(N-acylo)amidotiofosforano]-, 5'-O-[(N-acylo)amidoditiofosforano]nukleozydów |
| US20130143835A1 (en) * | 2011-12-05 | 2013-06-06 | Medivir Ab | HCV Polymerase Inhibitors |
| CN105934438A (zh) * | 2013-11-27 | 2016-09-07 | 艾登尼克斯药业有限公司 | 用于治疗肝癌的核苷酸 |
| KR102398714B1 (ko) * | 2014-08-25 | 2022-05-17 | 메디비르 아베 | 암 치료를 위한 우리딘의 디옥솔란 유사체 |
-
2015
- 2015-08-24 KR KR1020207008682A patent/KR102398714B1/ko active Active
- 2015-08-24 CN CN202010199579.4A patent/CN111269264A/zh active Pending
- 2015-08-24 HR HRP20201023TT patent/HRP20201023T1/hr unknown
- 2015-08-24 MX MX2017002328A patent/MX369649B/es active IP Right Grant
- 2015-08-24 WO PCT/EP2015/069370 patent/WO2016030335A1/en not_active Ceased
- 2015-08-24 HU HUE15756888A patent/HUE050705T2/hu unknown
- 2015-08-24 PT PT157568882T patent/PT3186244T/pt unknown
- 2015-08-24 AU AU2015308988A patent/AU2015308988C1/en active Active
- 2015-08-24 DK DK19177824.0T patent/DK3572410T3/da active
- 2015-08-24 PL PL19177824.0T patent/PL3572410T3/pl unknown
- 2015-08-24 PT PT191778240T patent/PT3572410T/pt unknown
- 2015-08-24 HU HUE19177824A patent/HUE059640T2/hu unknown
- 2015-08-24 PL PL15756888T patent/PL3186244T3/pl unknown
- 2015-08-24 KR KR1020177008235A patent/KR102396905B1/ko active Active
- 2015-08-24 CN CN201911149251.5A patent/CN110804072B/zh active Active
- 2015-08-24 EP EP15756888.2A patent/EP3186244B1/en active Active
- 2015-08-24 CN CN201911148331.9A patent/CN110790789B/zh active Active
- 2015-08-24 NZ NZ729118A patent/NZ729118A/en unknown
- 2015-08-24 DK DK15756888.2T patent/DK3186244T3/da active
- 2015-08-24 CN CN201580056640.7A patent/CN107074826B/zh active Active
- 2015-08-24 CA CA2956251A patent/CA2956251C/en active Active
- 2015-08-24 CA CA3128645A patent/CA3128645C/en active Active
- 2015-08-24 NZ NZ762628A patent/NZ762628A/en unknown
- 2015-08-24 EP EP19177824.0A patent/EP3572410B1/en active Active
- 2015-08-24 JP JP2017511226A patent/JP6663424B2/ja active Active
- 2015-08-24 SG SG10202001117YA patent/SG10202001117YA/en unknown
- 2015-08-24 EA EA201890648A patent/EA033300B1/ru not_active IP Right Cessation
- 2015-08-24 SG SG11201701172SA patent/SG11201701172SA/en unknown
- 2015-08-24 EA EA201790328A patent/EA031106B1/ru not_active IP Right Cessation
- 2015-08-24 MY MYPI2017700615A patent/MY188089A/en unknown
- 2015-08-24 ES ES15756888T patent/ES2796089T3/es active Active
- 2015-08-24 BR BR112017003898-6A patent/BR112017003898B1/pt active IP Right Grant
- 2015-08-24 SG SG10201911558UA patent/SG10201911558UA/en unknown
- 2015-08-24 US US15/506,692 patent/US10144750B2/en active Active
- 2015-08-24 ES ES19177824T patent/ES2927212T3/es active Active
-
2017
- 2017-01-30 IL IL250344A patent/IL250344B/en active IP Right Grant
- 2017-01-31 PH PH12017500184A patent/PH12017500184A1/en unknown
- 2017-02-22 MY MYPI2021007010A patent/MY198325A/en unknown
-
2018
- 2018-03-20 AU AU2018201980A patent/AU2018201980B2/en active Active
- 2018-05-02 ZA ZA2018/02864A patent/ZA201802864B/en unknown
- 2018-12-03 US US16/208,083 patent/US10336780B2/en active Active
-
2019
- 2019-05-21 IL IL266766A patent/IL266766B/en active IP Right Grant
- 2019-07-01 US US16/459,165 patent/US10654877B2/en active Active
- 2019-08-19 PH PH12019501919A patent/PH12019501919A1/en unknown
-
2020
- 2020-02-14 JP JP2020023051A patent/JP6905609B2/ja active Active
- 2020-04-13 US US16/847,477 patent/US10822360B2/en active Active
- 2020-05-22 CY CY20201100469T patent/CY1122945T1/el unknown
- 2020-11-02 US US17/087,483 patent/US11447511B2/en active Active
-
2022
- 2022-09-19 US US17/948,050 patent/US20230117570A1/en not_active Abandoned
-
2023
- 2023-05-31 US US18/326,992 patent/US20230382931A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2796089T3 (es) | Análogos de dioxano de uridina para el tratamiento de cáncer | |
| HK40014376B (en) | Dioxolane analogues of uridine for the treatment of cancer | |
| HK40014377B (en) | Dioxolane analogues of uridine for the treatment of cancer | |
| HK40011623B (en) | Dioxolane analogues of uridine for the treatment of cancer | |
| HK40011623A (en) | Dioxolane analogues of uridine for the treatment of cancer | |
| TWI695841B (zh) | 治療癌症之前藥 | |
| HK1240591A1 (en) | Dioxolane analogues of uridine for the treatment of cancer | |
| HK1240591B (en) | Dioxolane analogues of uridine for the treatment of cancer | |
| HK40020872A (en) | Dioxolane analogues of uridine for the treatment of cancer | |
| HK40014376A (en) | Dioxolane analogues of uridine for the treatment of cancer | |
| HK40014377A (en) | Dioxolane analogues of uridine for the treatment of cancer | |
| HK1235405A1 (en) | Dioxolane analogues of uridine for the treatment of cancer |